Get Help Now

Wisconsin | FAQs

Is Actos still on the market? What if I get bladder cancer from it? Does FDA approval mean I can’t sue?

During the summer of 2011, the U.S. Food and Drug Administration (FDA) updated Actos warnings to reflect a possible increased risk of bladder cancer among Actos users. However, as of July 1, 2012, Actos remains on the market in the United States. 

The same is not true in other countries. In 2011, France suspended prescriptions of pioglitazone (Actos) and Germany suspended new prescriptions of the drug.

While Actos still has FDA approval and is on the market in the United States, you still retain your legal rights if you develop bladder cancer. Actos users who develop bladder cancer should contact an experienced Milwaukee class action lawyer as soon as possible to learn more about their rights and potential recovery.

You should not have to suffer the financial, physical, and emotional consequences of Actos bladder cancer without someone fighting for your fair and just compensation. While your lawyer cannot go back and ask your doctor to prescribe another drug to treat your Type 2 diabetes, your lawyer can fight hard for your recovery of past, current, and future medical bills, lost income, out-of-pocket expenses, and pain and suffering.

To learn more, please contact the experienced Milwaukee Actos bladder cancer lawyers of Hupy and Abraham today. Our Wisconsin Actos attorneys can be reached via this website or by calling 1-800-800-5678 or 414-223-4800. We look forward to the opportunity to speak with you and to potentially helping you through this difficult time.

Jason F. Abraham
Managing Partner, Hupy and Abraham

2017 Hupy and Abraham, S.C. Coloring Contest

2017 Hupy and Abraham, S.C. Coloring Contest

2017 Coloring Contest by Hupy and Abraham, S.C.

Request Information +
Motorcycle Event Calendar

Motorcycle Event Calendar

The motorcycle lawyers of Hupy and Abraham have put together a magnetic calendar for riders highlighting the most exciting events of 2017.

Request Information +